Skip to main content
. Author manuscript; available in PMC: 2018 Nov 15.
Published in final edited form as: Bioconjug Chem. 2017 Oct 13;28(11):2756–2771. doi: 10.1021/acs.bioconjchem.7b00502

Figure 6.

Figure 6

B16-F10 melanoma cell viability obtained at 24 h (A) and 48 h (B) after incubation with peptides or nanoparticles. The concentration of the peptide in the conjugate is ca. 10% (w/w) of the conjugate concentration based on AAA (hence, the maximum peptide concentration for the conjugates is ca. 0.1 mg/mL, which is equivalent to the second point in the curves for the peptides, MUT30 and TRP2). The results of an in vitro DC maturation study (C) measured various dendritic cell maturation markers as an indicator of a nanoparticle’s ability to generate an immune response without an adjuvant. The composite maturation index reported in this figure represents an unweighted average of the expression of CD80, CD86, and MHCII normalized to the iDC (untreated) population. iDC: immature DCs; LPS: lipopolysaccharide (* represents p < 0.05 compared to the iDC population, as analyzed using ANOVA with a Tukey post-test); see Figure S10.